What we’re about
Welcome to the newest virtual home of the Philadelphia Area Java Users’ Group, twice rated by Sun as one of the world’s top Java User Groups! The Philly JUG’s main objective is to provide great learning events for our membership, and if you look at our history we’ve done just that. Over the past fifteen+ years the Philly JUG has done quite a bit of growing up. Very few of you might remember our first meeting, where about 35 members sat on the floor in the office of a long departed dot com. If you have been to a meeting recently you know how far we have come.
Current Philly JugMaster: Jason Young.
Upcoming events (1)
See all- Simpler Java Build Tools with Object Oriented ProgrammingCertara, Radnor, PA
The Java language is known to be performant, easy to use, and with great IDE support, but Java build tools like Maven or Gradle do not always live up to that reputation. This talk will explore why build tooling is fundamentally such a difficult domain to work in, and how common concepts from object-oriented programming have the potential to simplify the build tool experience. We will end with a demonstration of an experimental new Java build tool "Mill" that makes use of these ideas, proving out the idea that Java build tooling has the potential to be much faster, safer, and easier than it is today.
About the Speaker
Li Haoyi
Li Haoyi graduated from MIT, has built infrastructure for high-growth companies like Dropbox and Databricks, and has been a major contributor to the open source community on Github. Haoyi has deep experience in the JVM and has used it professionally to build cloud infrastructure, distributed backend systems, programming languages, high-performance web applications, and much more.About the Sponsor
Certara (https://www.certara.com)
Certara accelerates medicines to patients, using biosimulation (modeling and simulation) and technology-enabled services to transform drug discovery and development. Our integrated and proprietary end-to-end platform with generative AI technology, biosimulation, regulatory science, and market access solutions combined with our global 1,400+ strong team of scientists and experts enable informed decision-making, higher R&D productivity, and improved patient outcomes.
